These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35020476)

  • 1. The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.
    Scully KJ; Palani G; Zheng H; Moheet A; Putman MS
    Diabetes Technol Ther; 2022 Jun; 24(6):446-452. PubMed ID: 35020476
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
    Rizzi A; Tartaglione L; Lucaccini Paoli L; Leo ML; Popolla V; Viti L; Barberio A; Di Leo M; Pontecorvi A; Pitocco D
    Diabetes Obes Metab; 2024 Sep; 26(9):4078-4086. PubMed ID: 39010292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study.
    Bassi M; Franzone D; Dufour F; Spacco G; Cresta F; d'Annunzio G; Tantari G; Calevo MG; Castellani C; Minuto N; Casciaro R
    Front Endocrinol (Lausanne); 2024; 15():1347141. PubMed ID: 38966218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
    Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
    Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology.
    Pinsker JE; Müller L; Constantin A; Leas S; Manning M; McElwee Malloy M; Singh H; Habif S
    Diabetes Technol Ther; 2021 Feb; 23(2):120-127. PubMed ID: 32846114
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: Impact on glycemic control and neuropsychological tests in the real world.
    Amigó J; Ortiz-Zúñiga Á; de Urbina AMO; Sánchez M; Dos-Santos M; Abad M; Cuadra F; Simó R; Hernández C; Simó-Servat O
    Diabetes Res Clin Pract; 2023 Jul; 201():110730. PubMed ID: 37236365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
    Beck RW; Kanapka LG; Breton MD; Brown SA; Wadwa RP; Buckingham BA; Kollman C; Kovatchev B
    Diabetes Technol Ther; 2023 May; 25(5):329-342. PubMed ID: 37067353
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology.
    Breton MD; Kovatchev BP
    Diabetes Technol Ther; 2021 Sep; 23(9):601-608. PubMed ID: 33784196
    [No Abstract]   [Full Text] [Related]  

  • 11. A clinical review of the t:slim X2 insulin pump.
    Berget C; Lange S; Messer L; Forlenza GP
    Expert Opin Drug Deliv; 2020 Dec; 17(12):1675-1687. PubMed ID: 32842794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatments for managing cystic fibrosis-related diabetes.
    Onady GM; Stolfi A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD004730. PubMed ID: 33075159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-Month Effectiveness of Advanced
    Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
    Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of Control-IQ™ technology automated insulin delivery in pregnancy: A case series with qualitative interviews.
    Wang XS; Dunlop AD; McKeen JA; Feig DS; Donovan LE
    Diabet Med; 2023 Jun; 40(6):e15086. PubMed ID: 36924086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes.
    Messer LH; Berget C; Pyle L; Vigers T; Cobry E; Driscoll KA; Forlenza GP
    Diabetes Technol Ther; 2021 Dec; 23(12):837-843. PubMed ID: 34096789
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
    Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
    Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
    Garg SK; Weinzimer SA; Tamborlane WV; Buckingham BA; Bode BW; Bailey TS; Brazg RL; Ilany J; Slover RH; Anderson SM; Bergenstal RM; Grosman B; Roy A; Cordero TL; Shin J; Lee SW; Kaufman FR
    Diabetes Technol Ther; 2017 Mar; 19(3):155-163. PubMed ID: 28134564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy Settings Associated with Optimal Outcomes for t:slim X2 with Control-IQ Technology in Real-World Clinical Care.
    Messer LH; Breton MD
    Diabetes Technol Ther; 2023 Dec; 25(12):877-882. PubMed ID: 37751154
    [No Abstract]   [Full Text] [Related]  

  • 20. Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed‑loop system: A randomized controlled trial.
    Elbarbary NS; Ismail EAR
    Diabetes Res Clin Pract; 2022 Sep; 191():110045. PubMed ID: 35987309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.